Kevin Weil, who led OpenAI's science unit until he left in April, has launched a startup that uses AI to speed up a key step in drug development, Bloomberg reported, according to TNW; TNW reported that Warp Sciences came out of stealth with $215M in funding, and that Lightspeed Venture Partners led the round, according to the company.[1] The company said the round values Warp at $865 million, and it came out of stealth on Oct. 22.[1] Warp is building a fully automated US lab for the work of making hundreds or thousands of versions of a promising molecule to improve it and cut side effects, a step drugmakers have long sent to cheaper, faster Chinese firms such as WuXi AppTec.[1] TNW reported that drugmakers' reliance on Chinese firms has grown riskier as US-China tensions reach drug supply chains, and that Warp wants to bring that work back to the US with a fully automated lab; some drugmakers also worry about sharing sensitive data with Chinese contractors, Weil told Bloomberg.[1]
AI drug startup Warp Sciences comes out of stealth with $215M
The round values Warp at $865 million; Warp is building a fully automated US lab for molecule work drugmakers have long sent to Chinese firms.
0 primary · 1 independent · 0 commentary · 0 vendorSources
- Ex-OpenAI science head Kevin Weil launches Warp Sciences with $215M TNW | Artificial-intelligence Independent